Current research on diffuse large B-cell lymphoma (DLBCL)
Understanding why CLL patients stop responding to treatment, and options for salvage therapies
What makes TGR-1202 different from other PI3K inhibitors?
How to manage relapsed/refractory MCL - new agents and unmet needs
From chemotherapy towards targeted therapies in CLL